Akebia Therapeutics, Inc.AKBANASDAQ
Loading
R&D Expenses Over TimeContracting
Percentile Rank38
3Y CAGR-27.8%
5Y CAGR-22.2%
Year-over-Year Change
Research and development spending
3Y CAGR
-27.8%/yr
vs -13.1%/yr prior
5Y CAGR
-22.2%/yr
Recent deceleration
Acceleration
-14.7pp
Decelerating
Percentile
P38
Within normal range
vs 5Y Ago
0.3x
Contraction
Streak
1 yr
Consecutive growthContracting
| Period | Value | YoY Change |
|---|---|---|
| 2025 | $62.36M | +65.6% |
| 2024 | $37.65M | -40.3% |
| 2023 | $63.08M | -62.0% |
| 2022 | $165.99M | +12.3% |
| 2021 | $147.85M | -32.3% |
| 2020 | $218.49M | -32.4% |
| 2019 | $322.97M | +11.0% |
| 2018 | $291.07M | +26.1% |
| 2017 | $230.89M | +99.4% |
| 2016 | $115.78M | - |